Simultaneous kidney-pancreas transplantation without antilymphocyte induction

Area of Science:

• Nephrology
• Transplantation Immunology
• Immunosuppression

Background:

• Potent immunosuppressive agents may enable simultaneous kidney-pancreas transplantation without antilymphocyte induction.
• Evaluating novel immunosuppression protocols is crucial for improving transplant outcomes.

Purpose of the Study:

• To assess the safety and efficacy of a tacrolimus-based immunosuppression regimen without antilymphocyte induction in simultaneous kidney-pancreas transplantation.
• To determine graft survival rates and complication incidence in patients receiving this protocol.

Main Methods:

• Analysis of 30 simultaneous kidney-pancreas transplantations using tacrolimus, mycophenolate mofetil, and steroids without antilymphocyte induction.
• Patients received either portal-enteric (P-E) or systemic bladder (S-B) drainage for pancreas grafts.
• Targeted tacrolimus trough levels of 15-20 ng/ml were maintained for the first 3 months post-transplant.

Main Results:

• Excellent immediate graft function was observed for both kidney and pancreas.
• One-year actuarial patient, kidney, and pancreas graft survival rates were 93%, 93%, and 90%, respectively.
• Nine patients (30%) experienced rejection episodes, with 7 receiving antilymphocyte therapy; graft loss occurred in 7% for pancreas and 3% for kidney.

Conclusions:

• Tacrolimus, mycophenolate mofetil, and prednisone immunosuppression without antilymphocyte induction is safe and effective for simultaneous kidney-pancreas transplantation.
• This regimen supports excellent long-term dual graft function and survival.
• The findings support the elimination of antilymphocyte induction in select kidney-pancreas transplant recipients.